wait, those drop outs were for both Ph 2A Part A (5 weeks) AND Ph 2A Part B (52 weeks). That's 57 weeeks combined, not 54.
It's a shame those patients that were grade 1 and 2 dizzy, lethargic, and/or disoriented dropped out so early. Assuming their symptoms were due to 2-73 and not something else (Alzheimers itself, another disease, old age, etc), those symptoms may have been only transient or could have resolved if Anavex had adjusted their dose, which is acceptable in an adaptive trial. Adding patients to an adaptive trial while it is in progress is also acceptable, but I don't think Anavex has done that.
Market Data 
Markets 
AI
